|  |
| --- |
| **Table S1.** Clinical data of the patients. |
| Patient no.  | Sex | Age | TNM stage | Histological grade |
| 1 | Male | 62 | T2N0M0 | III |
| 2 | Male | 60 | T1N0M0 | I |
| 3 | Male | 53 | T1N0M0 | III |
| 4 | Male | 86 | T1N0M0 | III |
| 5 | Male | 55 | T1N0M0 | II |
| 6 | Female | 74 | T2N0M0 | III |
| 7 | Male | 56 | T2N0M0 | III |
| 8 | Female | 76 | T3N0M0 | III |
| 9 | Male | 65 | T2N0M0 | II |
| 10 | Female | 69 | T2N0M0 | II |

**Table S2.** The oligonucleotides used in this study

|  |  |
| --- | --- |
| Namea | Sequence (5'→3‘） |
| miR-300 mimics (sense) | UAUACAAGGGCAGACUCUCUCU |
| NC (sense) | ACTACTGAGTGACAGTAGA |
| si-SP1-1 (sense) | CCUGGAGUGAUGCCUAAUAdTdT |
| si-SP1-2 (sense) | CAGCUUGGUAUCAUCACAAdTdT |
| si-SP1-3 (sense) | GGCAGACCUUUACAACUCAdTdT |
| miR-300 F | TATACAAGGGCAGACTCTCTCT |
| U6 F | TGCGGGTGCTCGCTTCGGCAGC |
| SP1 F | TGGCAGCAGTACCAATGGC |
| SP1 R | CCAGGTAGTCCTGTCAGAACTT |
| CDK6 F | CAATAGCAATGGCGAGATCA |
| CDK6 R | ACCTCGGAGAAGCTGAAACA |
| TGM2 F | TCAATGCCGACGTGGTAGAC |
| TGM2 R | TCAGGGAACGGTTGATGGAT |
| c-Met F | TGTCCCGAGAATGGTCATAA |
| c-Met R | AGGGAAGGAGTGGTACAACA |
| PTTG1 F | CCCGCCTCCCCTTGAGT |
| PTTG1 R | TCAAGCTCCCTCTCCTCATCA |
| SP1-utr-F | cCATATATATTTTTTGCTTTTGTATATCCTATATAGGAAACg |
| SP1-utr-R | tcgacGTTTCCTATATAGGATATACAAAAGCAAAAAATATATATGgagct |
| SP1-mut-F | cCATATATATTTTTTGCTTAACATATTCCTATATAGGAAACg |
| SP1-mut-R | tcgacGTTTCCTATATAGGAATATGTTAAGCAAAAAATATATATGgagct |
| Site1 in the ChIP Assay-F | GCCTGTCAAGGAGGGGTGGG |
| Site1 in the ChIP Assay-R | TGGTGAGGGCAGAGGTGTCT |
| Site2 in the ChIP Assay-F | TTTGAGTTGTTAGCAGGTTT |
| Site2 in the ChIP Assay-R | CCTCACTCCTTTCTTCCTAG |
| Hsa-mir-300 probe | 5’-DIG-AGAGAGAGTCTGCCCTTGTAT-DIG-3’. |

a F, forward primer; R, reverse primer.